Navigation Links
Omeros Corporation Files Registration Statement for Proposed Initial Public Offering

SEATTLE, Jan. 9 /PRNewswire/ -- Omeros Corporation announced today that it has filed a registration statement with the Securities and Exchange Commission relating to the proposed initial public offering of shares of its common stock. All shares of the common stock to be sold in the offering will be offered by Omeros. Deutsche Bank Securities Inc. will be acting as the sole book-running manager. Pacific Growth Equities, LLC will be acting as the co- lead manager, and Leerink Swan LLC and Needham & Company, LLC will be acting as co-managers. The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus may be obtained from Deutsche Bank Securities Inc. by mail, Attn: Prospectus Department, 100 Plaza One, Floor 2, Jersey City, NJ 07311, by telephone at (800)-503-4611 or by email:

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time that the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Omeros Corporation

Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has three ongoing PharmacoSurgery clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders.

Forward-looking Statements

This press release contains "forward-looking statements." These statements include, but are not limited to, those regarding Omeros' proposed initial public offering and expectations regarding its clinical development activities and the clinical benefits of its product candidates. These forward-looking statements are based on the current intent and expectations of the management of Omeros. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Omeros' actual results and the timing and outcome of events may differ materially from those expressed in or implied by the forward-looking statements because of risks associated with Omeros' clinical development activities, regulatory oversight, intellectual property rights and other risks. Omeros undertakes no obligation to update any forward-looking or other statements in this press release, whether as a result of new information, future events or otherwise. SOURCE Omeros Corporation

Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Genelex Corporation Defends Consumers Right to Obtain DNA Information:
2. Pharmos Corporation Completes Initial Closing of Private Placement
3. Pharmos Corporation Announces Board and Management Changes
4. Environmental Tectonics Corporation Announces Sale of Monoplace Hyperbaric Chambers
5. CuraGen Corporation Announces Appointment of Sean Cassidy as CFO
6. LifeCell Corporation Schedules 2008 Financial Guidance Release and Conference Call; January 7, 2008 at 10:00 A.M. Eastern
7. Pharmos Corporation Announces President & COO Alan L. Rubino to Leave Company
8. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
9. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
10. FMC Corporation and Pronova BioPharma Announce Agreement To Develop New Alginate-Based Capsule Products
11. Genaera Corporation to Participate in Diabetes and Obesity Panel at RBC Capital Markets Healthcare Conference
Post Your Comments:
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, ... of the Supplyframe Design Lab . Located in Pasadena, Calif., the Design ... of how hardware projects are designed, built and brought to market. , The ...
(Date:6/23/2016)... BEACH, Calif. , June 23, 2016  Blueprint ... new biological discoveries to the medical community, has closed ... co-founder Matthew Nunez . "We have ... us with the capital we need to meet our ... will essentially provide us the runway to complete validation ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory ... technical consulting, provides a free webinar on Performing Quality Investigations: Getting ... at 12pm CT at no charge. , Incomplete investigations are still a major ...
(Date:6/22/2016)... June 22, 2016 Cell Applications, Inc. ... them to produce up to one billion human ... within one week. These high-quality, consistent stem cells ... cells and spend more time doing meaningful, relevant ... proprietary, high-volume manufacturing process that produces affordable, reliable ...
Breaking Biology Technology:
(Date:4/28/2016)... and BANGALORE, India , April 28, ... Systems, a product subsidiary of Infosys (NYSE: INFY ... announced a global partnership that will provide end ... use mobile banking and payment services.      (Logo: ... key innovation area for financial services, but it also plays ...
(Date:4/19/2016)... 2016 The new GEZE SecuLogic ... web-based "all-in-one" system solution for all door components. It ... the door interface with integration authorization management system, and ... The minimal dimensions of the access control and the ... installations offer considerable freedom of design with regard to ...
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting Medicaid ... setting a new clinical standard in telehealth thanks to ... leveraging the higi platform, IMPOWER patients can routinely track ... and body mass index, and, when they opt in, ... convenient visit to a local retail location at no ...
Breaking Biology News(10 mins):